More than 450 employees at The Cigna Group have signed a petition challenging the company’s decision to end GLP-1 weight-loss coverage for its workforce, formalizing a notable Cigna employees GLP-1 coverage petition effort that has so far not changed the company’s policy.
What Prompted This Cigna Employees GLP-1 Coverage Petition
Cigna stopped covering GLP-1s for weight loss through its employee health plan July 1. The company still covers the drugs for diabetes. In the wake of the decision, hundreds of Cigna employees detailed their experiences with GLP-1s in a petition sent to leadership in early July, according to a Sept. 2 report from WFSB.
One Employee’s Personal Account Behind This Petition
The employee who started the petition told the news outlet that she had tried to lose weight in a variety of ways over the years. While a gastric bypass surgery helped her prepare for a knee replacement, her doctor also recommended GLP-1s, which proved successful.
The Financial Impact Behind This Cigna Employees GLP-1 Coverage Petition
The employee said her out-of-pocket cost for GLP-1s was roughly $25 per month with Cigna’s coverage, but the drugs now cost around $500 per month. Despite the petition’s traction, the employee said Cigna is not changing its policy.
Why This Cost Increase Illustrates the Stakes for Affected Employees
A jump from $25 to approximately $500 per month represents a twentyfold increase in out-of-pocket cost for employees who relied on GLP-1 coverage, illustrating the significant financial burden this policy change has placed on workers who found the medication effective for weight management.
Cigna’s Response to This Employees GLP-1 Coverage Petition
“As an employer, we regularly make updates to our health coverage to maintain a plan that meets the needs of our unique employee base, while also managing affordability for all those who rely on it. We understand that this change is very personal for some employees, and we appreciated their willingness to share their stories with us directly. The decision to end coverage of GLP-1s for weight loss was made carefully, with research and input from leaders across the company, including clinical leaders,” a company spokesperson told Becker’s. “We will continue to support our employees on their health journeys through our Omada coaching platform and several other resources for weight management covered by our medical plan.”
Why Cigna’s Alternative Resources May Not Satisfy Petitioners
While Cigna points to its Omada coaching platform and other weight management resources as continued support, these alternatives don’t directly address the core financial concern petitioners raised, since coaching and non-pharmaceutical resources don’t replace the specific clinical effectiveness employees like the petition’s originator reported experiencing with GLP-1 medications.
The Contradiction Within Cigna’s Broader GLP-1 Business Strategy
Cigna’s choice to drop this coverage for its own employees follows the company building out GLP-1 benefit programs for its employer clients. In May 2025, the company said about half of Evernorth Health Services’ clients were covering GLP-1 costs for weight loss. About 15% to 20% of clients under the insurance branch, Cigna Healthcare, were doing the same, tending to be smaller employers.
Why This Contrast Draws Scrutiny
The gap between Cigna actively promoting and building GLP-1 coverage strategies for its external employer clients while simultaneously eliminating that same coverage for its own roughly 67,700 employees creates a notable tension that petition signers and outside observers may view as inconsistent with the company’s public positioning on GLP-1 access.
What This Cigna Employees GLP-1 Coverage Petition Means Going Forward
With Cigna confirming it will not reverse the policy despite the petition’s traction, affected employees will need to continue absorbing the substantially higher out-of-pocket costs or explore alternative resources like the company’s Omada coaching platform. Given Cigna’s continued expansion of GLP-1 benefit programs for external employer clients, this internal policy reversal may continue to draw scrutiny from employees and outside observers questioning why the company’s own workforce doesn’t receive the same coverage options it markets to its clients.
What to Watch Going Forward
As this dispute continues, industry observers will likely watch whether other large employers, including fellow insurers, face similar internal pushback if they pursue comparable GLP-1 coverage rollbacks amid broader industry cost pressures. Given the scale of this Cigna employees GLP-1 coverage petition, with more than 450 signatures despite the company’s confirmed refusal to reverse course, this episode may serve as a notable case study in the growing tension between employer cost-containment strategies and employee demand for GLP-1 access as these medications remain a significant driver of rising healthcare costs nationally.
For more healthcare industry updates, insights and news, visit DistilINFO. Click here to subscribe to stay informed.
